10-Q: Oruka Therapeutics Advances Psoriasis Programs

Oruka Therapeutics, a clinical-stage biopharmaceutical company, reported increased losses in Q2 2025 as it advances its lead psoriasis programs, ORKA-001 and ORKA-002, into clinical trials.

Summary

• Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications.
• The company reported a net loss of $24.6 million for the three months ended June 30, 2025, compared to $22.2 million for the same period in 2024.
• For the six months ended June 30, 2025, the net loss was $45.6 million, up from $29.3 million for the period from February 6, 2024 (inception) to June 30, 2024.
• Research and development (R&D) expenses increased by 29% to $24.1 million for the three months ended June 30, 2025, and by 84% to $44.0 million for the six months ended June 30, 2025, driven by increased personnel, stock-based compensation, and CMO/CRO expenses.
• General and administrative (G&A) expenses increased by 54% to $4.3 million for the three months ended June 30, 2025, and by 112% to $9.5 million for the six months ended June 30, 2025, primarily due to increased personnel and stock-based compensation.
• As of June 30, 2025, the company had $351.5 million in cash, cash equivalents, and marketable securities.
• Management expects existing cash, cash equivalents, and marketable securities to fund operating plans for at least twelve months from the filing date.
• The lead program, ORKA-001 (targeting IL-23p19 for PsO), commenced dosing in a Phase 2a clinical trial in patients with moderate-to-severe PsO in Q3 2025.
• The co-lead program, ORKA-002 (targeting IL-17A/F for PsO, PsA), initiated dosing of healthy volunteers in a Phase 1 trial in Q2 2025.
• Both ORKA-001 and ORKA-002 incorporate YTE half-life extension technology, aiming for less frequent dosing (e.g., once or twice per year for ORKA-001).
• The company accrued an additional milestone payment of $3.0 million under the ORKA-001 License Agreement in Q3 2025 due to the Phase 2a trial initiation.
• A third mAb program, ORKA-003, is in the pipeline, targeting an undisclosed pathway for inflammatory dermatology conditions.
• The company completed a reverse recapitalization and merger with ARCA biopharma, Inc. on August 29, 2024, and subsequently changed its name to Oruka Therapeutics, Inc. and ticker to ORKA.
• Significant capital raises occurred in 2024, including a Pre-Closing Financing of approximately $275.0 million gross proceeds and a PIPE Financing of approximately $188.7 million net proceeds.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While the company is incurring significant losses typical of a clinical-stage biopharma, it is well-capitalized for the near term ($351.5M cash, cash equivalents, and marketable securities expected to last 12+ months). Key programs (ORKA-001 and ORKA-002) are progressing into significant clinical trial phases (Phase 2a and Phase 1 respectively), and the half-life extension technology offers a potential competitive advantage. However, the substantial cash burn, reliance on future capital raises, and inherent risks of drug development temper the positive outlook.

Positives

• Strong cash, cash equivalents, and marketable securities balance of $351.5 million as of June 30, 2025, providing at least twelve months of funding.
• Successful advancement of ORKA-001 into a Phase 2a clinical trial for moderate-to-severe psoriasis, indicating progress in the lead program.
• Initiation of a Phase 1 clinical trial for ORKA-002, demonstrating pipeline progression.
• Both lead programs, ORKA-001 and ORKA-002, utilize half-life extension technology, which could enable less frequent dosing (e.g., once or twice per year for ORKA-001) and potentially offer a competitive advantage.
• FDA clearance of the Investigational New Drug (IND) application and Health Canada clearance of the Clinical Trial Application (CTA) for the Phase 2a trial of ORKA-001.
• The company has a third mAb program, ORKA-003, providing potential for future indication expansion and combination opportunities.
• Significant capital raised in 2024 (Pre-Closing Financing of $275.0 million gross and PIPE Financing of $188.7 million net) has bolstered the company's financial position for R&D.

Negatives

• Increased net loss for the three months ended June 30, 2025, to $24.6 million from $22.2 million in the prior year period.
• Substantial increase in net loss for the six months ended June 30, 2025, to $45.6 million from $29.3 million in the prior year period.
• Significant increase in research and development expenses (29% for Q2, 84% for H1 2025) and general and administrative expenses (54% for Q2, 112% for H1 2025), indicating high cash burn.
• The company has not generated any revenue from product sales since inception and does not expect to in the foreseeable future.
• Reliance on future financing to fund operations beyond the next twelve months, with no assurance of availability or favorable terms.
• The company has a limited operating history and no products approved for commercial sale, making future profitability uncertain.
• The long-term safety and efficacy of half-life extension technologies in humans are unknown, and the technology may not demonstrate the same properties as in preclinical studies.

Risks

• Drug development and regulatory approval processes are costly, time-consuming, and highly uncertain, with no guarantee of success.
• Substantial dependence on the success of ORKA-001 and ORKA-002; failure of these programs would significantly harm the business.
• Projected development goals and timelines may not be achieved, leading to delays and increased expenses.
• Competition from entities with greater financial resources and expertise in research, development, manufacturing, and marketing.
• Potential failure to meet chemistry, manufacturing, and control (CMC) requirements for programs.
• Lengthy and unpredictable FDA and foreign regulatory approval processes, which may lead to delays or failure to obtain approvals.
• Ongoing regulatory obligations and potential restrictions on product use even if approval is obtained.
• Uncertainty in obtaining and protecting patents and other proprietary rights, with potential for infringement claims or challenges to intellectual property.
• Reliance on third parties (CROs, CMOs, Paragon) for preclinical studies, clinical trials, and manufacturing, with risks of non-compliance or performance issues.
• Potential adverse effects from the U.S. BIOSECURE Act, trade restrictions, and other foreign regulatory requirements affecting foreign CROs and CMOs (e.g., WuXi Biologics).
• Difficulties in managing organizational growth and attracting/retaining highly qualified key personnel.
• Risk of security or data privacy breaches in information technology systems, potentially leading to costs, liabilities, and operational disruption.
• Exposure to costly and damaging product liability claims, with insurance potentially not covering all damages.
• Adverse U.S. legislative or regulatory tax changes (e.g., Inflation Reduction Act, Tax Cuts and Jobs Act changes to R&D expensing) could negatively impact financial condition.
• Market price volatility of common stock due to clinical trial results, financial projections, regulatory actions, and macroeconomic conditions.
• Future sales of shares by existing stockholders could cause stock price decline due to dilution.
• Potential for future capital raises to cause dilution to stockholders or impose restrictive covenants.
• Estimates of market opportunity and growth forecasts may be inaccurate, and business may not grow as anticipated.
• Potential for internal programs to compete with each other, limiting future revenue.

Future Outlook

Oruka Therapeutics expects to continue incurring substantial losses for the foreseeable future as it invests heavily in research and development, including advancing product candidates into larger, more expensive clinical trials and preparing for potential commercialization. The company anticipates an increase in personnel headcount to support R&D expansion and public company operations. Management expects existing cash, cash equivalents, and marketable securities to fund operating plans for at least twelve months from the filing date, but acknowledges the need for additional financing in the future to complete development, obtain marketing approval, and commercialize products. The company aims to share interim data from the ORKA-001 Phase 1 trial in September 2025 and from the ORKA-002 Phase 1 trial around year-end 2025. Efficacy and response duration data from the ORKA-001 Phase 2a study are expected in the second half of 2026. The company also plans to pursue a sequential combination regimen (ORKA-021) of ORKA-002 followed by ORKA-001.

Management Comments

• Our strategy is to apply antibody engineering and format innovations to validated modes of action, which we believe will enable us to improve meaningfully upon the efficacy and dosing regimens of standard-of-care medicines while significantly reducing technical and biological risk.
• We believe that our focused strategy, differentiated portfolio, and deep expertise position us to set a new treatment standard in large I&I markets with continued unmet need.
• We expect that our existing cash, cash equivalents, and marketable securities will be sufficient to fund our operating plans for at least twelve months from the date of filing of this Quarterly Report.
• We expect to continue to incur substantial losses for the foreseeable future, and our transition to profitability will depend upon successful development, approval and commercialization of our product candidates and upon achievement of sufficient revenues to support our cost structure.
• Based on recent precedent for PsO, we anticipate that the entire development program from first-in-human to biologics license application (BLA) filing could take as little as six to seven years based on the averages for recently approved medicines.
• We view ORKA-002 and ORKA-001 as highly complementary. Patients with moderate-to-severe PsO that have purely skin manifestations are most often treated with IL-23 inhibitors due to the high efficacy and tolerability of this mechanism. However, for patients who also have joint involvement, or signs and symptoms of PsA, an IL-17 inhibitor is typically used due to its efficacy in addressing both skin and joint symptoms.

Industry Context

Oruka Therapeutics operates in the highly competitive biopharmaceutical industry, specifically targeting inflammatory and immunology (I&I) indications like psoriasis and psoriatic arthritis. The company's strategy of applying antibody engineering and half-life extension technology to validated mechanisms (IL-23p19 and IL-17A/F) aims to differentiate its product candidates by improving efficacy and reducing dosing frequency compared to existing standard-of-care medicines. This approach seeks to address unmet needs in large I&I markets. The industry faces ongoing challenges including lengthy and costly drug development, intense competition from established players, and evolving regulatory landscapes, including potential impacts from legislation like the BIOSECURE Act and broader economic policies affecting drug pricing and supply chains.

Comparison to Industry Standards

• ORKA-001 and ORKA-002 are designed to bind IL-17A/F at similar epitopes and affinity ranges as bimekizumab (Bimzelx), a recently approved therapy, but incorporate half-life extension technology for more convenient dosing intervals.
• The company's goal for ORKA-001 to achieve higher response rates than established IL-23p19 therapies in PsO while requiring less frequent dosing (subcutaneous injection as infrequently as once or twice per year) aims to surpass current market offerings.
• The anticipated development timeline from first-in-human to BLA filing for PsO of six to seven years is based on averages for recently approved medicines, suggesting an aggressive but potentially achievable timeline if no significant delays occur.
• The company's focus on IL-23 and IL-17A/F inhibition aligns with validated mechanisms in the treatment of psoriatic diseases, leveraging established pathways rather than entirely novel targets, which may reduce biological risk compared to some industry peers pursuing entirely new mechanisms.

Corporate Governance

Legal Proceedings

• The company is not currently party to any material legal proceedings.

Related Party Transactions

• Fairmount Healthcare Fund II, L.P. (Fairmount) beneficially owns more than 5% of the company's capital stock and has one representative on the Board.
• Fairmount beneficially owns more than 5% of Paragon Therapeutics, Inc. (Paragon) and has the contractual right to approve the appointment of Paragon's executive officers.
• The company entered into two Antibody Discovery and Option Agreements with Paragon and Paruka Holding, LLC (Paruka) in March 2024.
• The company entered into License Agreements with Paragon for ORKA-001 (December 2024) and ORKA-002 (February 2025).
• Milestone payments of $4.0 million for each of the ORKA-001 and ORKA-002 License Agreements were incurred and expensed as of June 30, 2025.
• An additional milestone payment of $3.0 million under the ORKA-001 License Agreement was accrued in Q3 2025.
• The company recognized $4.2 million and $5.7 million of expenses in connection with services provided by Paragon and Paruka under the Option Agreements for the three and six months ended June 30, 2025, respectively.
• A warrant to purchase 596,930 shares of Company Common Stock was issued to Paruka on December 31, 2024, as part of the Paruka Warrant Obligation.
• The estimated fair value of the warrant to be granted to Paruka on December 31, 2025, was $6.2 million as of June 30, 2025, with $3.1 million recognized as stock-based compensation expense for the six months ended June 30, 2025.

Stakeholder Impact

• **Shareholders**: Potential for dilution from future capital raises. Stock price volatility is a risk. Current losses impact shareholder equity, but significant cash reserves provide stability for ongoing development.
• **Employees**: Continued hiring in R&D and administrative roles, along with stock-based compensation plans (2024 Stock Incentive Plan, ESPP), indicate investment in human capital and alignment of employee interests with company performance.
• **Customers (Future Patients)**: Advancement of ORKA-001 and ORKA-002 into clinical trials offers potential for new, improved treatment options for psoriasis and psoriatic arthritis, particularly with the promise of less frequent dosing.
• **Suppliers/Creditors**: Increased R&D spending benefits CROs, CMOs, and other third-party vendors. The company's strong cash position suggests good ability to meet short-term obligations to creditors.
• **Regulatory Authorities**: Ongoing engagement with FDA and Health Canada for clinical trial approvals and future marketing authorizations. Compliance with regulations is critical for product development and commercialization.

Next Steps

• Share interim data from ORKA-001 Phase 1 trial in healthy volunteers, including initial pharmacokinetic data, at the European Academy of Dermatology & Venereology (EADV) Congress in September 2025.
• Share interim data from ORKA-002 Phase 1 trial in healthy volunteers, including initial pharmacokinetic data, around year end 2025.
• Share efficacy and response duration data from ORKA-001 Phase 2a study in the second half of 2026.
• Initiate a Phase 2 clinical trial of ORKA-002 in the first half of 2026.
• Grant Paruka a warrant to purchase 1.00% of outstanding shares as of December 31, 2025, as part of the Paruka Warrant Obligation.
• Continue to invest in research and development activities related to the continued development of programs and any future programs, including investments in manufacturing.
• Seek regulatory and marketing approvals and reimbursement for product candidates.
• Establish a sales, marketing, and distribution infrastructure to commercialize any approved products.
• Maintain, protect, and expand the intellectual property portfolio.
• Evaluate additional opportunities to enhance capabilities and expand the development pipeline through collaborations, alliances, or licensing arrangements.

Key Dates

Recommendation

Oruka Therapeutics is a clinical-stage biopharmaceutical company with a strong cash position ($351.5 million) that is expected to fund operations for at least the next 12 months. This provides a solid runway for its lead programs, ORKA-001 and ORKA-002, which are progressing into significant clinical trial phases (Phase 2a and Phase 1, respectively). The half-life extension technology is a compelling differentiator that could offer a competitive advantage in the large I&I market. However, the company is incurring substantial and increasing losses, typical for its stage, and will require significant future capital raises, which could lead to dilution. The inherent risks of drug development, including clinical trial failures, regulatory hurdles, and intense competition, remain high. Given the early stage of its pipeline and the significant cash burn, a 'hold' recommendation is appropriate. Investors should monitor clinical trial data readouts, particularly for ORKA-001 in September 2025 and ORKA-002 at year-end 2025, and the company's ability to secure future financing without excessive dilution.

Keywords

Biopharmaceutical, Psoriasis, Inflammatory diseases, Immunology, Monoclonal antibody, Clinical stage, ORKA-001, ORKA-002, IL-23p19, IL-17A/F, Half-life extension, Clinical trials, Drug development, SEC filing, Biotech, Nasdaq, ORKA